Bernstein sees TI’s likely price hike benefiting Infineon, Renesas stock
Akero Therapeutics, Inc. (NASDAQ:AKRO) Senior Vice President, Commercial Strategy, Patrick Lamy, sold 2,000 shares of common stock on June 16, 2025, for a total of $108,271. The sales were executed in two transactions, with prices ranging from $53.817 to $55.092. The transaction occurs as AKRO trades near its 52-week high of $58.40, having delivered an impressive 152% return over the past year. According to InvestingPro analysis, the stock is currently fairly valued.
On the same day, Lamy also exercised options to acquire 2,000 shares of Akero Therapeutics common stock at a price of $19.87, totaling $39,740.
Following these transactions, Lamy directly owns 32,573 shares of Akero Therapeutics.
The reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 6, 2025.
In other recent news, Akero Therapeutics has been the subject of several analyst reports following its recent earnings and clinical trial updates. Akero reported promising results from its Phase 2b SYMMETRY trial, indicating significant improvements in liver fibrosis for patients with MASH-related cirrhosis. The trial results were published in the New England Journal of Medicine, highlighting the potential of Akero’s efruxifermin (EFX) treatment. Jefferies maintains a Buy rating on Akero with a $75 price target, emphasizing the strong data from Akero’s FGF21 therapy trials. Meanwhile, Citi adjusted its price target from $80 to $78, maintaining a Buy rating, and noted the importance of comprehensive liver outcomes data for FDA approval. Morgan Stanley (NYSE:MS) also revised its price target to $84 from $90, maintaining an Overweight rating and citing a conservative shift in the anticipated U.S. launch timeline for EFX. Additionally, Clear Street initiated coverage with a Buy rating and a $49 price target, noting EFX’s "best-in-class potential" for treating NASH. Akero’s financial position remains strong, with $1.1 billion in cash reserves, expected to support operations through critical Phase III trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.